Who are "Rush" regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ioflupane I 123, Goprelto, Datscan, Vyvanse, Focalin, Pemolin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rush-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

"Rush" regimen — Competitive Intelligence Brief

"Rush" regimen ("Rush" regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amphetamine. Area: Central Nervous System.

marketed Amphetamine Dopamine transporter Central Nervous System Biologic Live · refreshed every 30 min

Target snapshot

"Rush" regimen ("Rush" regimen) — Pablo Rodríguez del Rio. Rush is a stimulant that increases alertness and energy by affecting the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
"Rush" regimen TARGET	"Rush" regimen	Pablo Rodríguez del Rio	marketed	Amphetamine	Dopamine transporter
Ioflupane I 123	IOFLUPANE	Ge Hlthcare Inc	marketed	Radioactive Diagnostic Agent [EPC]	Dopamine transporter (DaT)	2023-01-01
Goprelto	COCAINE		marketed	cocaine	Sodium-dependent dopamine transporter	2017-01-01
Datscan	IOFLUPANE I 123	Ge Hlthcare Inc	marketed	Radioactive Diagnostic Agent [EPC]	Sodium-dependent dopamine transporter	2011-01-01
Vyvanse	LISDEXAMFETAMINE	Takeda	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2007-01-01
Focalin	DEXMETHYLPHENIDATE	Novartis	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2001-01-01
Pemolin	PEMOLINE		marketed	pemoline	Sodium-dependent dopamine transporter	1975-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amphetamine class)

Pablo Rodríguez del Rio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). "Rush" regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/rush-regimen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab